Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 3-8 , 15 November 2003

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

  • Francesca Bellomi

      Affiliations

    • Department of Experimental Medicine and Pathology, Section of Virology, University “La Sapienza”, V.le di Porta Tiburtina, 28, Rome 00185, Italy
    • ,
  • Carolina Scagnolari

      Affiliations

    • Department of Experimental Medicine and Pathology, Section of Virology, University “La Sapienza”, V.le di Porta Tiburtina, 28, Rome 00185, Italy
    • ,
  • Valentina Tomassini

      Affiliations

    • Department of Neurological Science, University “La Sapienza”, V.le dell'Università, 30, Rome 00185, Italy
    • ,
  • Claudio Gasperini

      Affiliations

    • Department of Neurosciences, “St. Camillo-Forlanini” Hospital, Via Circonvallazione Gianicolense, 87, Rome 00152, Italy
    • ,
  • Andrea Paolillo

      Affiliations

    • Department of Neurological Science, University “La Sapienza”, V.le dell'Università, 30, Rome 00185, Italy
    • ,
  • Carlo Pozzilli

      Affiliations

    • Department of Neurological Science, University “La Sapienza”, V.le dell'Università, 30, Rome 00185, Italy
    • ,
  • Guido Antonelli

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39-6-4940-525; fax: +39-6-4474-1236.
    • Department of Experimental Medicine and Pathology, Section of Virology, University “La Sapienza”, V.le di Porta Tiburtina, 28, Rome 00185, Italy

Received 27 September 2002 ,Revised 8 April 2003 ,Accepted 14 April 2003.

References 

  1. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur. Cytokine Network. 1999;10(3):413–422
  2. Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, et al.  Mapping of IFN-β epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J. Interferon Cytokine Res. 2001;21:931–941
  3. Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A, et al.  Finnish Beta-Interferon Study Group   Neutralizing antibodies reduce MxA protein induction in interferons-beta-1a-treated MS patients. Neurology. 2002;58:1786–1790
  4. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, et al.  The Multiple Sclerosis Collaborative Research Group (MSCRG)   Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 1998;50:1266–1272
  5. Cook SD, Quinless JR, Jotkowitz A, Beaton P  The Neutralizing Antibody Study Group . Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology. 2001;57:1080–1084
  6. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999;52:1239–1243
  7. The IFNB Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group . Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 1996;47:889–894
  8. The IFN B Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285
  9. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology. 1999;52:1277–1279
  10. Fernández O, Mayorga C, Luque G, Guerrero M, Guerrero R, Leyva L, et al.  Study of binding and neutralizing antibodies to interferon-β in two groups of relapsing–remitting multiple sclerosis patients. J. Neurol. 2001;248:383–388
  11. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, et al.  The Danish Multiple Sclerosis Study Group   Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann. Neurol. 2000;48:706–712
  12. Kivisakk P, Alm GV, Fredrikson S, Link H. Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis. Eur. J. Neurol. 2000;7:27–34
  13. Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, et al.  Neutralizing and binding antibodies to IFN beta: relative frequency in relapsing–remitting multiple scerosis patients treated with different interferon beta preparations. J. Interferon Cytokine Res. 2002;22:207–213
  14. USAN Council List No 359 . News name. Interferon beta-1a. Clin. Pharmacol. Ther. 1994;55:478–480
  15. Utsumi J, Mizuno Y, Hosoi K, Okano K, Sawada R, Kajitani M, et al.  Characterization of four different mammalian-cell-derived recombinant human interferon-β1s. Eur. J. Biochem. 1989;181:545–553
  16. Runkel L, Meier W, Blake R, Pepinsky RB, Karpusas M, Whitty A, et al.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN beta). Pharmacol. Res. 1998;15:641–649
  17. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive. Neurology. 1998;51:1698–1702
  18. Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, et al.  Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol. Sci. 1999;168:131–136
  19. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, et al.  Development of neutralizing antibodies in patients with relapsing–remitting multiple sclerosis treated with IFN-β1a. J. Interferon Cytokine Res. 1998;18:345–350
  20. Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorilli M, et al.  A 6-year clinical and MRI follow-up study of patients with relapsing–remitting multiple sclerosis treated with interferon-beta. Eur. J. Neurol. 2002;9(6):645–655
  21. Pozzilli C, Koudriavtseva T. Interferon beta-1a. Baillieres Clin. Neurol. 1997;6(3):481–493
  22. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986;119:558–573
  23. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferon by antibody: II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 2001;21:743–755
  24. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology. 1997;49(3):647–650
  25. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells. Cytokines Cell Mol. Ther. 1997;3:27–32
  26. Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, et al.  A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J. Interferon Cytokine Res. 1998;18:1025–1030
  27. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000;48:95–100
  28. Antonelli G, Giannelli G, Currenti M, Simeoni E, Milella M, Schiraldi O, et al.  Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha. Int. Hepatol. Commun. 1995;4:232–237
  29. Davis-Daneshfar A, Boni R, von Wussow P, Joller H, Burg G, Dummer R. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-α on immunoparameters in vivo. J. Immunother. 1997;20(3):208–213
  30. Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, et al.  Loss of interferon antibodies during prolonged interferon-alpha 2a therapy in hairy cell leukemia. Blood. 1991;4:792–798

PII: S0022-510X(03)00173-4

doi: 10.1016/S0022-510X(03)00173-4

Journal of the Neurological Sciences
Volume 215, Issue 1 , Pages 3-8 , 15 November 2003

Article Tools

* Image Usage & Resolution